JBC Transcription and Nuclear Factor Monoclonals

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M305080200 on June 10, 2003

J. Biol. Chem., Vol. 278, Issue 34, 31766-31773, August 22, 2003
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
278/34/31766    most recent
M305080200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Orrù, S.
Right arrow Articles by Esposito, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Orrù, S.
Right arrow Articles by Esposito, C.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Proteomics Identification of Acyl-acceptor and Acyl-donor Substrates for Transglutaminase in a Human Intestinal Epithelial Cell Line

IMPLICATIONS FOR CELIAC DISEASE*

Stefania Orrù {ddagger} §, Ivana Caputo § ¶, Alfonsina D'Amato {ddagger}, Margherita Ruoppolo || ** and Carla Esposito {ddagger} {ddagger}{ddagger}

From the {ddagger}Department of Chemistry, University of Salerno, 84081 Baronissi, Salerno, Italy, Department of Pediatrics & European Laboratory for the Investigation of Food-induced Diseases, University of Naples "Federico II," 80138 Naples, Italy, ||Department of Biochemistry and Medical Biotechnologies, University of Naples "Federico II," 80138 Naples, Italy, and **Centro di Ingegneria Genetica, Biotecnologie Avanzate, scarl, Naples 80138, Italy

Received for publication, May 14, 2003


    ABSTRACT
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Transglutaminase (TG)-catalyzed cross-linking of both intracellular and extracellular proteins is an important biochemical event. However, increased concentrations of cross-linked proteins have been observed in many disorders. Moreover, TG-catalyzed modification of proteins might generate new self-antigens responsible for the autoimmune response, as in celiac disease. The identification of available substrates may offer an understanding of how the TG-catalyzed post-translational modification has an impact on physiology and disease. We used a proteomic approach to identify TG-modified protein targets in human intestinal epithelial cells to determine the extent to which transglutaminase specifically contributes to celiac disease. Two probes were used for endogenous TG activity: 5-(biotinamido)pentylamine, which represents the acyl-acceptor, and a biotinylated glutamine-containing peptide, which represents the acyl-donor. This approach identified >25 proteins, which range from 30,000 to 300,000 Daltons and can serve as acyl-acceptor and/or acyl-donor for transglutaminase. Some of them were known transglutaminase substrates, whereas others had not been previously identified. These targets include proteins involved in cytoskeletal network organization, folding of proteins, transport processes, and miscellaneous metabolic functions.


    INTRODUCTION
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Transglutaminases (TGs)1 (EC 2.3.2.13 [EC] ) constitute a family of enzymes that catalyze the post-translational modification of proteins. Their calcium-dependent catalytic activity is exhibited toward {gamma}-carboxamide groups of peptide-bound glutamine residues and {epsilon}-amino groups of peptide-bound lysines, leading to an intrachain or interchain isopeptide bond. Low molecular weight amines may substitute lysines in transamidating reactions. In the absence of suitable amines, water may act as an acyl-acceptor substrate with the consequent deamidation of protein-bound glutamine residues (1, 2). Nine different TG genes have been characterized in mammalian species to date (3, 4). However, the biological significance of some gene products is completely unknown. Currently, distinct widely expressed TG molecular forms have been described, including plasma Factor XIIIa, keratinocyte TG (type I), tissue TG (type II), epidermal TG (type III), prostate TG (type IV), and TG V (4). TG enzymes are involved in many fundamental biological processes including the fibrin-clotting cascade (1), seminal vesicle coagulation (5), and cornification of the epidermis, hair, and nails (6, 7).

Despite the fact that tissue TG (tTG) has been studied extensively, its function remains an open question. tTG is expressed in selected mammalian tissues and seems involved in the regulation of several biological events including cellular proliferation, differentiation, and apoptosis (3, 8). Moreover, tTG has been found associated with the extracellular surface where it has been implicated in extracellular matrix organization (9, 10). tTG functions might therefore depend on its peculiar location in tissues. In particular, the presence of different accessible proteins able to act as substrates for the enzyme in specific cell type may determine the activity of tTG and its control. Up to now, few cases of tTG activity have been reported to be linked to the modulation of the function of specific substrate proteins. The cross-linking of retinoblastoma protein has been shown to be a key signal for the initiation of apoptosis (11, 12). Latent transforming growth factor-{beta} that is considered the major autocrine/paracrine inhibitory regulator in the intestinal epithelium is activated by tTG (13). Finally, tTG-mediated post-translational modifications of proteins may represent pathogenic mechanisms in diseases, including celiac disease (CD) (14). CD is an autoimmune pathology triggered in genetically predisposed patients by exposure to gliadin, a flour protein, thus evoking local immune reactions and mucosal atrophy (15). A model was postulated on the basis of the finding that tTG is the main target of immune response in CD (16) and that gliadin is able to act as a tTG substrate (17, 18). This model suggests that tTG catalyzes in situ the deamidation of specific glutamine residues present in immunodominant gluten peptides, which are recognized by CD4+ DQ2-restricted mucosal T cells (19, 20). However, the mucosal environment should be without amine donors to allow the occurrence of such reactions in vivo. Apart from the deamidation of gliadin peptide, tTG acts as hapten in the generation of antibodies against gliadin and itself, catalyzing the synthesis of heteromeric gliadin-tTG complexes that may provoke an immune response to tTG by stimulating normally silent B cells specific for tTG (21, 22). However, where tTG comes in contact with gliadin in the intestinal mucosa and how tTG-catalyzed post-translational modifications may occur remain to be investigated. It is conceivable that a primary pathogenic event of CD could happen at the level of the enterocytes, which are crucial to maintain barrier function between the luminal milieu and the internal environment. There is increasing evidence that enterocytes modulate immunological functions of the intestinal mucosa by expressing HLA class II antigens and presenting antigens to T-lymphocytes (23). Recently, an increased expression of tTG in celiac patients was reported in enterocytes, both at brush border and cytoplasm levels, as well as in the extracellular matrix. Moreover, by performing tTG assays in situ, it was discovered that accessible proteins act as acyl-acceptor and acyl-donor substrates in intestinal mucosa (24). Therefore, we focused on the identification of putative substrates of tTG in an enterocyte-like system. Achieving this goal represents a crucial step to clarify the role of the enzyme in CD. CaCo-2 cells, a human colon adenocarcinoma cell line, that represent a suitable model for the study of the enterocytes function in vitro (25) were used. In situ and in vitro tTG assays were performed using two probes for endogenous tTG activity: 5-(biotinamido)pentylamine, which represents the acylacceptor tTG substrate, and a synthetic biotinylated glutamine-containing peptide, which represents the acyl-donor tTG substrate. A proteomic approach was used to identify >25 endogenous proteins, both acyl-acceptor (Lys-donor) and acyl-donor (Gln-donor), that may represent the target of tTG catalytic action. Biological relevance of such potential in vivo tTG substrates is discussed relatively to the role of intestinal epithelial cells in CD pathogenesis.


    EXPERIMENTAL PROCEDURES
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Cell Culture—The human colon adenocarcinoma cell line CaCo-2 and Madin-Darby canine kidney (MDCK) cells were obtained from the Interlab Cell Line Collection (Centro di Biotecnologie Avanzate, Genova, Italy). CaCo-2 cells were cultured in 100 x 10-mm Petri dishes containing Dulbecco's modified Eagle's medium supplemented with 10% (v/v) fetal bovine serum, 1% (v/v) non-essential amino acids, 0.2 mM L-glutamine, 50 units/ml penicillin, and 50 µg/ml streptomycin (Invitrogen). MDCK cells were grown in minimum essential medium (Invitrogen) supplemented with 10% (v/v) fetal bovine serum, 10% (v/v) Earle's balanced salt solution, 50 units/ml penicillin, 50 µg/ml streptomycin, and 1% (v/v) non-essential amino acids. Cells were maintained at 37 °C in a 5% CO2, 95% air-humidified atmosphere and passaged twice in a week. In this study, CaCo-2 cells were used between the 16th and 25th passages. For the experiments, the cells were seeded at a density of 30 x 104/cm2. On the 3rd and 12th day post-confluence, cells were used for in situ treatments and alternatively were harvested to perform in vitro assays. A stable MDCK cell clone, MDCK-tTG, expressing recombinant tTG was previously obtained (26) and used for in situ assays.

In situ tTG Activity Assay—Two probes were used for labeling proteins in intact cells: 5-(biotinamido)pentylamine (BPNH2, Pierce), which represents the acyl-acceptor probe, and a biotinylated glutamine-containing hexapeptide (biotinyl-TVQQEL, A25 peptide) (27), which represents the acyl-donor probe. Cells were preincubated for 1 h in the presence of 1 mM BPNH2 or 1 mM A25 peptide in standard culture medium. To activate intracellular tTG, cells were treated for 30 min with the Ca2+-ionophore A-23187 (ICN) at the concentration of 10 µM. As A-23187 was dissolved in dimethyl sulfoxide, the maximal dimethyl sulfoxide concentration to which the cells were exposed was 0.1%. A trypan blue exclusion test was performed to determine the cell viability after A-23187 challenge. After the treatments, cells were washed twice with calcium-free and magnesium-free phosphate-buffered saline (PBS) solution and scraped in ice-cold buffer (HEPES, pH 7.5) containing 1 mM EGTA and protease inhibitors (20 µg/ml leupeptin, 0.5 mM benzamidine, 20 µg/ml aprotinin, and 0.2 mg/ml phenylmethylsulfonyl fluoride) (Sigma). The cell suspension was sonicated on ice four times for 10 s each and centrifuged at 15,000 x g for 10 min at 4 °C. Finally, the supernatant was used for further experiments.

In vitro tTG-mediated Labeling Assay—To perform in vitro tTG-mediated protein labeling, CaCo-2 cells were washed twice with PBS solution and scraped in ice-cold 10 mM HEPES, pH 7.5, containing 5 mM dithiothreitol and protease inhibitors. Cells were sonicated four times for 10 s each, and the homogenate was centrifuged at 15,000 x g for 10 min at 4 °C. The obtained supernatants (500 µg) were incubated at 37 °C for 2 h in a 50 mM HEPES buffer, pH 9.0, containing 10 mM dithiothreitol and 5 mM CaCl2 in the presence of 1 mM BPNH2 or, alternatively, 1 mM A25 peptide (final volume, 200 µl). In control samples, CaCl2 was replaced by 5 mM EGTA. tTG-catalyzed reactions were stopped by adding 8 µl of 0.4 M EDTA.

Immunoblotting—Aliquots of homogenates obtained by in situ and in vitro labeling were run on 10% SDS-PAGE and analyzed by Western blot using horseradish peroxidase (HRP)-conjugated streptavidin (Pierce) to reveal biotinylated proteic species according to the procedure described by Zhang et al. (28). To detect tTG, the same blots were stripped in 0.1 M Tris-HCl, pH 6.7, containing 0.1 M {beta}-mercaptoethanol and 2% SDS at 50 °C for 30 min, blocked in 5% nonfat milk solubilized in Tris-buffered saline buffer for 1 h, and incubated overnight with anti-tTG monoclonal antibody CUB 7402 (Neo-Markers) (1:1000 final dilution) in the blocking buffer. After four washes with Tris-buffered saline buffer containing 0.05% Tween 20, the blots were incubated for 2 h with the HRP-conjugated goat anti-mouse secondary antibody (Bio-Rad) diluted 1:3000 in the blocking buffer. The blots were washed as above, and immunocomplexes were revealed using the chemiluminescence detection kit (Pierce) according to manufacturer's instructions.

Cytochemistry—For cytochemical staining, cells were plated onto coverslips and preincubated for 1 h at 37 °C in the presence of 1 mM BPNH2 or 1 mM A25 peptide. Cells were then fixed in paraformaldehyde (3% in PBS) for 20 min and permeabilized with Triton X-100 (0.2% in PBS) for 4 min. After the incubation with 1% bovine serum albumin in PBS to reduce the background, cell were probed with fluorescein isothiocyanate-conjugated streptavidin (Santa Cruz Biotechnology) diluted 1:30 in 1% bovine serum albumin for 30 min. Control coverslips contained no biotinylated substrate. Cells were finally observed with an Axioplan 2 microscope (Zeiss), and images were acquired and analyzed by the KS300 software.

Purification of Labeled tTG Protein Substrates—The protein mixture containing tTG protein substrates labeled by BPNH2 was removed from the excess of the acyl-acceptor probe using a Sephadex PD10 pre-packed column (Amersham Biosciences) with PBS as eluent. 1-ml fractions were collected and monitored at 280 nm. The eluted proteins were pooled and analyzed by affinity chromatography with a pre-packed monomeric avidin column (Pierce) according to the procedure previously reported (29, 30). Biotinylated proteins were specifically eluted with a PBS buffer containing 2 mM biotin. The fractions containing labeled tTG protein substrates were pooled, desalted, and concentrated by Centricon-10 (Amicon) up to a final volume of 0.5–1 ml. Finally, the biotin-labeled protein mixture was analyzed by the SDS-PAGE on 10% linear slab gels. Molecular masses of protein bands were estimated by using Bio-Rad precision protein standards.

The protein mixture containing tTG protein substrates labeled by the A25 peptide was dialyzed against PBS at 4 °C for 24 h to remove the excess of acyl-donor probe. The protein mixture was then purified following the procedure described above.

In Gel Digestion of Proteins—Coomassie Blue-stained protein-containing bands were excised from the gel, cut in pieces, and washed first with acetonitrile and then with 0.1 M ammonium bicarbonate. Protein samples were reduced by incubation in 10 mM dithiothreitol for 45 min at 56 °C and alkylated with 55 mM iodoacetamide in 0.1 M ammonium bicarbonate for 30 min at room temperature in the dark as described previously (31). The gel particles were then washed with 0.1 M ammonium bicarbonate and acetonitrile. Enzymatic digestions were carried out with modified trypsin (Roche Applied Science) (12.5 ng/µl) in 50 mM ammonium bicarbonate, pH 8.5, at 4 °C for 45 min. The enzymatic solution was then removed, and a new aliquot of the buffer solution was added to the gel particles. The digestions were incubated at 37 °C for 18 h. A minimum reaction volume sufficient for complete rehydration of the gel was used. Peptides were then extracted by washing the gel particles in three steps: (1) water; (2) 0.2% trifluoroacetic acid; and (3) acetonitrile at 37 °C for 15 min/step and then lyophilized.

Peptide Mapping—MALDI spectra were recorded using a reflectron Voyager DE PRO MALDI-time-of-flight mass spectrometer (Applied Biosystems). An aliquot of the peptide mixture (1 µl) was added to a MALDI matrix solution, and then 1 µl was spotted onto a stainless steel sample plate and allowed to dry. The MALDI matrixes used in this study were {alpha}-cyano-4-hydroxycinnamic acid (Sigma, 10 mg/ml in acetonitrile, 0.2% trifluoroacetic acid, 7:3 (v/v)) in a sample:matrix ratio of 1:1 and sinapinic acid (Sigma, 10 mg/ml in acetonitrile, 0.2% trifluoroacetic acid, 6:4 (v/v)) in a sample:matrix ratio of 1:5. Spectra were acquired both in a linear and in a reflectron mode. The mass range was calibrated using the [M+H]+ ions from the standard peptide mixture provided by the manufacturers. Raw data were analyzed using computer software provided by the manufacturers.

In cases where the identity of the proteins present could not be established by MALDI analysis alone, the peptide mixtures were further analyzed by µLCMS/MS using a Q-ToF hybrid mass spectrometer (Micromass) equipped with a Z-spray source and coupled on-line with a capillary chromatography system. After loading, the peptide mixture (10 µl) was first concentrated and washed at 30 µl/min onto a reverse-phase pre-column (Waters) using 0.1% formic acid as eluent. The sample was then fractionated using a C18 reverse-phase capillary column (75 µm x 10 mm) at a flow rate of 200 nl/min using a linear gradient of eluent B (0.1% formic acid in acetonitrile) in A (0.1% formic acid) from 5 to 60% in 10 min. Elution was monitored on the mass spectrometer without any splitting device. The mass spectrometer was set up in a data-dependent MS/MS mode where a full scan spectrum (m/z range from 500 to 2000 Da/e) was followed by a tandem mass spectrum. The precursor ion was selected as the most intense peak of the previous scan. A ramp of collision energy between 30 and 60 eV was applied depending on the mass and charge of the precursor ion. ProteinLynx Global Server software, provided by the manufacturers, was used to analyze raw MS and MS/MS data and identify proteins.

Data Base Searching—MALDI raw data were inserted into several web-available search programs (Mascot at www.matrixscience.com, MS-Fit at prospector.ucsf.edu, and ProFound at prowl.rockefeller.edu) to search the non-redundant protein sequence data base (NCBInr), taking advantage of the specificity of the proteolytic enzyme used for the hydrolysis and the taxonomic category of the sample. Proteins were identified by selecting Homo sapiens as taxonomic category. No protein molecular weight was considered for the MatrixScience program, whereas the standard protein molecular weight ranges were used for the other programs (trypsin as enzyme, up to five missed cleavages; cysteines as S-carbamidomethylcysteines; unmodified N- and C-terminal ends; and methionines both as unmodified and as oxidized). Only experimental values within 0.03% accuracy were recorded. Three independent sets of experiments were performed.


    RESULTS
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
In situ tTG-mediated Labeling of Cellular Proteins—CaCo-2 cells that constitutively express tTG (32) were used for in vivo transamidation experiments. In particular, CaCo-2 cells were studied both after 3 days post-confluence when they were still colonocytes to a large extent (undifferentiated cells) and after 12 days post-confluence when they were most similar to ileal enterocytes. To detect the acyl-donor (Gln-donor) and the acylacceptor (Lys-donor) tTG substrates, the acyl-acceptor BPNH2 and the acyl-donor A25 peptide were used as probes, respectively, as described under "Experimental Procedures." To investigate the probes uptake, a cytochemistry approach was used. Fig. 1 shows the intracellular localization of both biotinylated substrates in 3-day-post-confluent CaCo-2 cells. Similar results were obtained when 12-day-post-confluent cells were analyzed (data not shown). To visualize the proteins into which BPNH2 had been incorporated, samples were subjected to SDS-PAGE, transferred to a nitrocellulose membrane, and probed with an HRP-conjugated streptavidin (Fig. 2A, lanes 1 and 3). Because tTG is a calcium-activated enzyme, intracellular levels of calcium were elevated by treating the cells with the Ca2+-ionophore A-23187. Increasing intracellular calcium levels resulted in a significant increase in tTG-catalyzed incorporation of BPNH2 into proteins in both different stages of CaCo-2 cells (Fig. 2A, lanes 2 and 4). The profile of proteins modified by tTG in the cells did not differ between the two extremes of CaCo-2 cell expression. However, the cross-linking was somewhat more evident in differentiated cells than in undifferentiated one, judging from the total amount labeled (compare lane 4 with lane 2). To determine whether the increase in the level of cross-links in situ observed in differentiated cells coincided with an increase of tTG expression, blots were stripped and reprobed with the monoclonal tTG antibody (Fig. 2B). tTG protein levels were higher in 12-day-post-confluent CaCo-2 cells than in 3-day-post-confluent CaCo-2 cells (Fig. 2B, lanes 3 and 4 compared with lanes 1 and 2). Moreover, in the presence of increased calcium ions level, the decrease of the tTG monomer migrating at 78 kDa contemporary with the presence of a band at high molecular mass revealed that tTG takes part in the formation of heteropolymers together with protein substrates.



View larger version (32K):
[in this window]
[in a new window]
 
FIG. 1.
Microscopic visualization of BPNH2 and A25 peptide uptake in 3-day-post-confluent CaCo-2 cells. The biotinylated probes were detected using fluorescein isothiocyanate-conjugated streptavidin. NT, non-treated cells.

 


View larger version (60K):
[in this window]
[in a new window]
 
FIG. 2.
Immunoblots of the tTG-catalyzed incorporation of BPNH2 and A25 peptide into proteins of intact cells. CaCo-2 cells at 3 and 12 days post-confluence were treated with BPNH2 (A, lanes 1–4) or A25 peptide (C, lanes 1–4)in the absence (–) or in the presence (+) of the Ca2+-ionophore A-23187 as described under "Experimental Procedures." Moreover, MDCK-tTG cells were also treated with BPNH2 (A, lanes 5 and 6). For Western blot analyses, 80 µg of proteins for each sample of CaCo-2 cells and 80 µg of proteins for each sample of MDCK-tTG cells were loaded and probed with HRP-conjugated streptavidin. Blots were then stripped and reprobed with the monoclonal anti-tTG CUB 7402 to visualize the tTG content in cells treated with BPNH2 (B) or with A25 peptide (D). Positions at which molecule mass standards (kDa) migrated are indicated at the right with arrows.

 

To establish the specificity of the tTG-modified intracellular proteins, MCDK cells stably transfected with wild-type tTG were used as a control. The drastically decreased number of proteins that might act as acyl-donors in the transamidating reaction (Fig. 2A, lanes 5 and 6) suggests that proteins in CaCo-2 cells are selectively modified by tTG, even though tTG protein levels are higher in MDCK-tTG cells than in CaCo-2 cells as shown in Fig. 2B, lanes 5 and 6.

Parallel experiments were performed to detect the acyl-acceptor (Lys-donor) tTG substrates in CaCo-2 cells using the acyl-donor A25 peptide (Fig. 2C). Also, in this case, it was possible to detect the presence of several protein bands spread over a wide molecular weight range only after intracellular tTG activation (lanes 2 and 4). Moreover, the labeled protein patterns seemed not to be different between 3 and 12 days post-confluence. It is worth noting that the Lys-donor tTG substrates pattern seemed to be different from the Gln-donor pattern (see panel C and compare with panel A), thus indicating that different proteins can act as tTG substrates when using the two selected probes. Very high molecular weight polymers, including tTG not able to enter the gel mesh, were also detected in the gel wells when the blot was stripped and reprobed with the monoclonal antibody CUB 7402 (Fig. 1D) (33).

To isolate the Gln-donor and Lys-donor tTG protein substrates in CaCo-2 cells, the biotin-labeled proteins were separately purified from the whole CaCo-2 protein homogenate (8 mg) by an avidin-affinity chromatographic step. Such a strategy led to the isolation of the labeled proteins in a single step, thus simplifying the protein mixture. The eluted proteins were finally separated by SDS-PAGE analysis. The obtained Coomassie Blue-stained patterns displayed very few faint protein bands (data not shown). Considering the low efficiency of the in situ assay increasing the amount of tTG labeled proteins so that they could be successfully purified and visualized on a Coomassie Blue-stained gel, the substrate reactivity of CaCo-2 cell proteins was investigated by an in vitro assay.

In vitro tTG-mediated Labeling of Cellular Proteins—Homogenates from 3- and 12-day-post-confluence cultures were incubated separately with BPNH2 and A25 peptide as described in "Experimental Procedures." An aliquot (20 µg) of each reaction mixture was assayed by performing a Western blot analysis using the HRP-conjugated streptavidin as a detecting probe. The tTG protein substrates labeled in vitro with BPNH2 were shown in the Fig. 3A, lanes 3 and 4. The incorporation was Ca2+-dependent because no signals were detected in the samples incubated in the presence of EGTA (data not shown). Comparing the pattern relative to in vitro labeling to the correspondent patterns obtained in situ (Fig. 3A, lanes 3 and 4 and lanes 1 and 2), a strong similarity in the number and distribution of the bands with few minor differences was observed. Similar results were obtained when the A25 peptide was used (Fig. 3B). Hence, an in vitro assay was performed to label the Gln-donor and Lys-donor tTG substrates. Cellular homogenates (8 mg) obtained from 3-day-post-confluent CaCo-2 cells were incubated with both the acyl-acceptor BPNH2 and the acyl-donor A25 peptide, respectively. The reaction mixtures were purified by the affinity chromatographic step to separate BPNH2-labeled as well as A25 peptide-labeled proteins from the whole protein homogenate. The eluted proteins were finally separated by SDS-PAGE analysis.



View larger version (69K):
[in this window]
[in a new window]
 
FIG. 3.
Comparison of in situ and in vitro tTG-specific labeling pattern obtained with BPNH2 (A) and A25 peptide (B) at different stages of CaCo-2 cell differentiation (3 and 12 days post-confluence). 80 µg of proteins from CaCo-2 cells treated with BPNH2 (A, lanes 1 and 2) or, alternatively, with A25 peptide (B, lane 1 and 2) in the presence of Ca2+-ionophore A-23187 were subjected to a Western blot analysis with HRP-conjugated streptavidin to detect cellular tTG substrates. In parallel experiments, homogenates from CaCo-2 cells were used for an in vitro tTG assay in the presence of BPNH2 or A25 peptide and 20 µg of proteins from each reaction mixture were analyzed by Western blot. A and B, lanes 3 and 4, the labeling patterns obtained with BPNH2 and A25 peptide, respectively. Positions at which molecule mass standards (kDa) migrated are indicated at the right with arrows.

 

Identification of tTG Protein Substrates in CaCo-2 Cells— Fig. 4 displays the electrophoretic pattern of the BPNH2-labeled proteins, whereas the A25 peptide-labeled species are shown in Fig. 5. The better electrophoretic resolved bands were excised from the gel slabs. In the case of the Gln-donor proteins selected by BPNH2 (Fig. 4), two protein bands, AQ and BQ, were removed in the mass range between 150 and 250 kDa. Three species, CQ, DQ, and EQ, were selected in the 75–100-kDa mass range. The bands FQ, GQ, IQ, and LQ were cut out from the gel in the mass range between 50 and 75 kDa. Finally, the species MQ was selected in the mass range below 37 kDa. In the case of the Lys-donor species specifically labeled by the A25 peptide (Fig. 5), one band, AK, was excised in the mass range between 150 and 250 kDa; two species, BK and CK, were excised from the 75–100-kDa mass range; four protein bands, DK, EK, FK, and GK, were selected between 50 and 75 kDa; and finally, bands IK and LK were selected from the 37–50-kDa range.



View larger version (35K):
[in this window]
[in a new window]
 
FIG. 4.
Identification of acyl-donor transglutaminase protein substrates. SDS-PAGE analysis of BPNH2-labeled proteins. Excised Gln-donor protein bands are labeled. A list of the identified proteins is reported. *, percentage in brackets of the sequence coverage obtained by MALDI/MS analysis.

 


View larger version (41K):
[in this window]
[in a new window]
 
FIG. 5.
Identification of acyl-acceptor transglutaminase protein substrates. SDS-PAGE analysis of A25 peptide-labeled proteins. Excised Lys-donor protein bands are labeled. A list of the identified proteins is reported. *, the percentage in brackets of the sequence coverage obtained by MALDI/MS analysis is shown.

 

Each protein band was reduced, carboxymethylated, and digested with trypsin as described under "Experimental Procedures." The peptide mixtures were then directly analyzed using MALDI/MS. Such treatments meant that diagnostic peptide mixtures could be produced for each unknown protein and translated in a list of peptide molecular masses. For each sample, MALDI/MS measurements were repeated at least three times, changing MALDI matrix and/or acquisition parameters. m/z signals registered in the different mass spectra obtained were then collected as a single set. The different sets of values were separately investigated by searching the non-redundant NCBI protein data base through several web-available programs to identify tTG protein substrates.

As an example, MALDI/MS analyses related to band AQ (Fig. 4) at approximately 250 kDa gave rise to >100 m/z signals. These signals were analyzed by independent search programs exploring the non-redundant NCBI protein data base. This search ranked fatty-acid synthase (molecular mass of 275 kDa) in the first position of the output list of probable candidates with a sequence coverage of 30%. Some of the original m/z signals were not assigned to the fatty-acid synthase sequence, and the search performed on the unassigned signals led to identification of another two Gln-donor proteins, filamin 1 (molecular mass of 283 kDa) and spectrin {alpha} (molecular mass of 285 kDa), characterized by a sequence coverage of 21 and 19%, respectively.

In some cases it was not possible to identify protein species by their MALDI spectra. This inconvenience was because of several factors such as low protein amounts and complex comigrating protein mixtures. These samples were then analyzed by µLCMS/MS to confirm previous identification and to extend the characterization to non-assigned protein gel bands. The eluate of the reverse-phase chromatography was directly analyzed using the Q-ToF mass spectrometer, which was able to fragment "on-line" up to 8 co-eluting peptides. The peptide mass data and their relative internal sequence information were then used to explore NCBInr using the ProteinLynx Global Server software. This procedure led to the unambiguous identification of the proteins as the peptide mass along with internal sequence information represent a unique fingerprint for a protein. The accuracy and sensitivity of the µLCMS/MS analysis meant that multiple proteins could be identified within a single protein band.

Figs. 4 and 5 report the Gln-donor and Lys-donor protein substrates of tTG identified in this study both by MALDI/MS and by µLCMS/MS analysis. Identifications obtained by means of MALDI/MS are followed by the sequence coverage of the peptide mapping reported in brackets.

The whole strategy employed in this study led to the definition of 14 proteins in the Gln-donor group and 18 in the Lysdonor set. It is interesting to note that among the protein substrates, five of them acted as complete tTG substrates: tumor rejection antigen-1; heat shock (Hsp) 90-kDa protein; Hsp 70-kDa protein 8; Hsp 70/90-organizing protein; and T-complex protein-1{epsilon} subunit.


    DISCUSSION
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
The interaction of tTG with multiple substrates, both intracellular and extracellular, is essential for those proteins to carry out their biological functions. The tTG-catalyzed post-translational modification of the substrate proteins, either by polymerization or by covalent linkage to soluble low molecular weight molecules such as amines or peptides, can alter the physical-chemical characteristics of the substrates, thus playing a key role in modulating their biological activity. However, in some circumstances, tTG-catalyzed post-translational modifications of proteins may generate auto-antibodies as it happens in auto-immune disorders such as CD (14). Such a phenomenon was explained by a mechanism where tTG, acting as a hapten in the generation of antibodies against gliadin and itself, catalyzes the synthesis of heteromeric gliadin-tTG complexes. Such complexes may provoke an immune response to tTG by stimulating normally silent tTG-specific B cells. Biagi et al. (23) have suggested that enterocytes might have a role in the induction of the immune response in CD, acting as antigen-presenting cells. Recently, an accumulation of active tTG as well as the presence of Gln-donor and Lys-donor tTG substrates have been demonstrated in the enterocytes of celiac patients compared with controls (24, 34). The identification of the potentially dangerous substrates of tTG in intestinal mucosa may therefore offer an understanding of the role of the enzyme in CD.

In the absence of viable cell lines from human small intestine, we used the CaCo-2 cell line. Although this cell line is derived from a colonic neoplasm, it shows features of small intestinal differentiation in the post-confluent state (25). Moreover, it is important to emphasize that undifferentiated CaCo-2 cells were used to study both gluten toxicity (35) and early biochemical events such as the enterocyte apoptosis in CD (36). Therefore, the experiments to label in vivo tTG substrates were performed using CaCo-2 cells both after 3 days post-confluence when they were still colonocytes to a large extent (undifferentiated cells) and 12 days post-confluence when they were most similar to ileal enterocytes. The Western blot patterns, relative to 3 and 12 days post-confluence, are very similar to each other (Fig. 2), demonstrating that the ability of proteins to act as Gln-donor and Lys-donor is independent from the differentiation state. However, the specificity is high as demonstrated by the control. Especially, looking at other cell line, overexpressing the enzyme in which the pattern relative to the substrates appears to be different. Moreover, the overlapping patterns of labeled proteins obtained by performing in situ and in vitro assays suggest that the substrate proteins that became labeled in vitro could be available also in intact cells.

The proteomic strategy meant that it was possible to identify >25 tTG substrates ranging from 30 to 300 kDa (Figs. 1 and 2, panels B). Some of those proteins were known tTG substrates, whereas others had not previously been identified. It is interesting to note that some proteins were shown to be complete substrates of tTG, such as tumor rejection antigen-1, Hsp 90-kDa protein, Hsp 70-kDa protein 8, Hsp 70/90-organizing protein, and T-complex protein-1{epsilon} subunit.

In relation to their biological significance, the identified proteins fall into four groups (Table I). These targets include proteins involved in cytoskeletal network organization, folding of proteins, and transport processes. A fourth group finally consists of proteins involved in miscellaneous metabolic functions.


View this table:
[in this window]
[in a new window]
 
TABLE I
Functional classification of identified tTG protein substrates

 

The first group is represented by proteins involved in the organization of the cytoskeleton. The intestinal epithelium forms a barrier made of polarized cells joined by complex cell-cell adhesion systems that are connected to the cytoskeleton. Proteins of the cytoskeleton play an important role in both generation and maintenance of epithelial polarity (37). The basolateral membrane domain of the mature enterocytes is scaffolded by a spectrin-based membrane cytoskeleton consisting primarily of actin, myosin, spectrin, and ankyrin (38). In this case, it was shown that spectrin and myosin are able to act as acyl-donor and acyl-acceptor, respectively. Furthermore, we identified the protein filamin known to link actin filaments to membrane glycoproteins as the acyl-donor (39). Cytoskeletal proteins have been shown to be cross-linked by tTG, especially following the loss of cellular integrity, inducing apoptosis to prevent an inflammatory response (40). Moreover, it has been reported that tTG is associated with elements of the cytoskeleton, thus indicating its involvement in the organization of the cytoskeleton. tTG was in fact shown to be co-localized with the stress fibers via cross-linking to myosin by virtue of auto-catalytic activity of the enzyme (41). In this study, we report that ezrin/radixin/moesin-binding phosphoprotein-50, a member of ezrin/radixin/moesin family of membrane-cytoskeletal adapters involved in the formation of microvilli, cell-cell adhesion, maintenance of cell shape, cell motility, and membrane trafficking (42), is able to act as a tTG Lys-donor substrate. Two elongation factors, types {alpha} and {gamma}, were shown to be able to act as tTG Lys-donor substrates. Elongation factor 1{alpha} is known as an actin-binding protein besides a cofactor of polypeptide elongation (43). Finally, Rho-associated coiled-coil-containing protein kinase 2 (ROCK-2) was shown to be a tTG acyl-donor substrate in CaCo-2 cells. ROCK-2 is critical for the assembly of the apical junctional proteins and actin-cytoskeleton organization during junctional formation in intestinal epithelia (44). Recent evidence suggests that ezrin/radixin/moesin proteins, ROCK-2 and elongation factor 1{alpha}, participate in signaling pathway involving the activation of members of the Rho-GT-Pase, a member of the Rho family (45). In summary, the present findings support the hypothesis that tTG-catalyzed post-translational modifications of proteins involved in cytoskeletal rearrangement are required to modulate their biological properties and influence their interactions with other proteins important for enterocyte survival.

The second group of proteins represents proteins with chaperone activities such as the Gln-donors Bip and T-complex protein-1{epsilon} subunit and the acyl-acceptor chaperonin 3 (that belongs to the chaperonin family Hsp60), Hsp70/90 organizing protein, nuclease-sensitive element-binding protein 1, and T-complex protein-1{epsilon} subunit. The T-complex protein-1{epsilon} subunit, which is able to act as a complete tTG-substrate, belongs to the T-complex protein chaperonin family, and it assists in vitro in the folding of actin and tubulin (46). In cellular model produced by us, several members of high molecular weight Hsp family and Hsp-like were found that are able to act as complete substrates for tTG. tTG is very specific, and the number of proteins able to act as glutaminyl and lysyl substrates is highly restricted. On this basis, it is interesting to underline that, in CaCo-2 cells, the number of proteins acting as complete substrates is exceptionally high. The expression of constitutively Hsps such as Hsp60, Hsp70, Hsp72, and Hsp90 and Bip (47) by enterocytes may be part of a protective mechanism developed by the intestinal epithelium to deal with noxious components in the intestinal lumen.

A third group represents proteins involved in transport processes. It was found that importin is able to act as a Lys-donor, whereas valosin and clathrin act as Gln-donors. It has been reported that tTG is involved in the receptor-mediated endocytosis process in different cellular systems (48). Monodansylcadaverine, a synthetic amine substrate of tTG widely used to inhibit tTG activity in vivo, was shown to inhibit the internalization of ligands via the clathrin-mediated endocytotic pathway (49). More recently, it has been reported that there is a functional and/or physical interaction between the cytoskeleton and the clathrin-mediated endocytic machinery (50). The present results suggest that the interaction between the Gln-donor clathrin and a Lys-donor cytoskeletal protein could be mediated by tTG activity. Based on this finding, it is interesting to note that gliadin peptides are transported inside enterocytes and processed by the intestinal mucosa (23). However, the mechanism of internalization of gliadin peptides is unknown. Therefore, it might be suggested that the transport process of gliadin is probably mediated by the clathrin-mediated endocytotic pathway and that an alteration of this process may be involved in the pathogenesis of CD enterocytes.

A fourth group is represented by miscellaneous proteins that are involved in different metabolic processes such as phosphoglycerate dehydrogenase that catalyzes the initiating step in the phosphorylated pathway of serine biosynthesis or fatty-acid synthase that is a key enzyme in lipid metabolism.

The data reported here demonstrate that in CaCo-2 cells there are tTG substrates. Obviously, substrate identification alone cannot explain CD specificity, but these results provide a platform that could support a broader understanding of how tTG participates in enterocyte metabolic processes. It is intriguing to suggest that tTG could come in contact with gliadin inside enterocytes and modify gliadin peptides by cross-linking to itself or to other acyl-acceptor substrates, thus originating neo-antigens recognized by the immune system. This mechanism could explain the existence of auto-antibodies in CD with several distinct specificities (51). An immune reaction was observed against the cytoskeleton in both children and adults with CD. In particular, anti-actin antibodies are shown to be more strongly associated with more severe degrees of villous atrophy (52). Furthermore, it is possible to hypothesize that gliadin peptides can trigger a cascade of events leading to the inappropriate presentation of tTG and cross-linked substrates to the immune system contributing to the immune aspect of CD. This mechanism could in part explain the increased prevalence of concomitant auto-immune diseases, such as collagen diseases, type I diabetes, auto-immune alopecia, hypophysitis, and others in CD patients with prolonged gluten exposure (53).

Studies are in progress to identify tTG substrates in bioptic specimens from CD patients and from controls. An alteration of the substrate profile might mean a different distribution of gliadin in the enterocytes of healthy controls and CD patients that is responsible for the deleterious effects evoked by gliadin in the celiac intestine.


    FOOTNOTES
 
* The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

§ Both authors contributed equally to this work. Back

{ddagger}{ddagger} To whom correspondence should be addressed: Dept. of Chemistry, University of Salerno, Via S. Allende, 84081 Baronissi, Salerno, Italy. Tel.: 39-089-965298; Fax: 39-089-965296; E-mail: cesposito{at}unisa.it.

1 The abbreviations used are: TG, transglutaminase; tTG, tissue transglutaminase; A25 peptide, biotinylated glutamine-containing hexapeptide (biotinyl-TVQQEL); BPNH2, 5-(biotinamido)pentylamine; CD, celiac disease; HRP, horseradish peroxidase; Hsp, heat shock protein; µLCMS/MS, capillary liquid chromatography/tandem mass spectrometry; MALDI, matrix-assisted laser desorption ionization; MDCK, Madin-Darby canine kidney; PBS, phosphate-buffered saline; ROCK-2, Rho-associated coiled-coil-containing protein kinase 2. Back



    REFERENCES
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Folk, J. E., and Finlayson, J. S. (1977) Adv. Protein Chem. 31, 1–133[Medline] [Order article via Infotrieve]
  2. Lorand, L., and Conrad, S. M. (1984) Mol. Cell. Biochem. 58, 9–35[CrossRef][Medline] [Order article via Infotrieve]
  3. Aeschlimann, D., and Paulsson, M. (1994) Thromb. Haemostasis 71, 402–415[Medline] [Order article via Infotrieve]
  4. Grenard, P., Bates, M. K., and Aeschlimann, D. (2001) J. Biol. Chem. 276, 33066–33078[Abstract/Free Full Text]
  5. Esposito, C., Pucci, P., Amoresano, A., Marino, G., Cozzolino, A., and Porta, R. (1996) J. Biol. Chem. 271, 27416–27423[Abstract/Free Full Text]
  6. Candi, E., Oddi, S., Terrinoni, A., Paradisi, A., Ranalli, M., Finazzi-Agrò, A., and Melino, G. (2001) J. Biol. Chem. 276, 35014–35023[Abstract/Free Full Text]
  7. Steinert, P. M., Candi, E., Tarsca, E., Marekov, L. N., Sette, M., Paci, M., Ciani, B., and Melino, G. (1999) Cell Death Differ. 6, 916–930[CrossRef][Medline] [Order article via Infotrieve]
  8. Griffin, M., Casadio, R., and Bergamini, C. M. (2002) Biochem. J. 368, 377–396[CrossRef][Medline] [Order article via Infotrieve]
  9. Aeschlimann, D., and Thomazy, V. (2000) Connect. Tissue Res. 4, 1–27[Medline] [Order article via Infotrieve]
  10. Akimov, S. S., and Belkin, A. M. (2001) Blood 98, 1567–1575[Abstract/Free Full Text]
  11. Oliviero, S., Amendola, A., Di Sano, F., Farrace, M. G., Fesus, L., Nemes, Z., Piredda, L., Spinedi, A., and Piacentini, M. (1997) Mol. Cell. Biol. 17, 6040–6048[Abstract]
  12. Melino, G., and Piacentini, M. (1998) FEBS Lett. 430, 59–63[CrossRef][Medline] [Order article via Infotrieve]
  13. Nunes, I., Gleizes, P. E., Metz, C. N., and Rifkin, D. B. (1997) J. Cell Biol. 136, 1151–1163[Abstract/Free Full Text]
  14. Kim, S.-Y., Jeitner, T. M., and Steinert, P. M. (2002) Neurochem. Int. 40, 85–103[CrossRef][Medline] [Order article via Infotrieve]
  15. Sollid, L. M. (2000) Annu. Rev. Immunol. 18, 53–81[CrossRef][Medline] [Order article via Infotrieve]
  16. Dieterich, W., Enhis, T., Bauer, M., Donner, P., Volta, U., Riecken, E. O., and Schuppan, D. (1997) Nat. Med. 3, 797–801[CrossRef][Medline] [Order article via Infotrieve]
  17. Porta, R., Gentile, V., Esposito, C., Mariniello, L., and Auricchio, S. (1990) Phytochemistry 29, 2801–2804[CrossRef]
  18. Martucci, S., and Corazza, G. R. (2002) Gastroenterology 122, 1729–1737[CrossRef][Medline] [Order article via Infotrieve]
  19. Fleckenstain, B., Molberg, Ø., Qiao, S.-W., Schmid, D. G., von der Mülbe, F., Elgstøen, K., Günther, J., and Sollid, L. M. (2002) J. Biol. Chem. 277, 34109–34116[Abstract/Free Full Text]
  20. Arentz-Hansen, H., McAdam, S. N., Molberg, Ø., Fleckenstain, B., Lundin, K. E. A., Jørgensen, T. J. D., Jung, G., Roepstorff, P., and Sollid, L. M. (2002) Gastroenterology 123, 803–809[CrossRef][Medline] [Order article via Infotrieve]
  21. Sollid, L. M., Molberg, Ø., McAdam, S., and Lundin, K. E. A. (1997) Gut 41, 851–852[Free Full Text]
  22. Molberg, Ø., McAdam, S. N., and Sollid, L. M. (2000) J. Pediatr. Gastroenterol. Nutr. 30, 232–240[CrossRef][Medline] [Order article via Infotrieve]
  23. Biagi, F., Zimmer, K. P., Thomas, P. D., Ellis, H. J., and Ciclitira, P. J. (1999) Q. J. Med. 92, 119–122
  24. Esposito, C., Paparo, F., Caputo, I., Porta, R., Salvati, M. V., Mazzarella, G., Auricchio, S., and Troncone, R. (2003) Am. J. Gastroenterol., in press
  25. Pinto, M., Robine-Leon, S., Appay, M.-D., Kedinger, M., Triadou, N., Dussaulux, E., Lacroix, B., Simon-Assmann, P., Haffen, K., Fogh, J., and Zweibaum, A. (1983) Biol. Cell 47, 323–330
  26. Esposito, C., Paparo, F., Caputo I., Rossi, M., Maglio, M., Not, T., Porta R., Auricchio S., Marzari R., and Troncone, R. (2002) Gut 51, 177–181[Abstract/Free Full Text]
  27. Ruoppolo, M., Orrù, S., D'Amato, A., Francese, S., Rovero, P., Marino, G., and Esposito, C. (2003) Protein Sci. 12, 1290–1297[Abstract/Free Full Text]
  28. Zhang, J., Lesort, M., Guttman, R. P., and Johnson, G. V. W. (1998) J. Biol. Chem. 273, 2288–2295[Abstract/Free Full Text]
  29. Lee, K. N., Maxwell, M. D., Patterson, M. K., Birckbichler, P. J., Jr., and Conway, E. (1992) Biochim. Biophys. Acta 1136, 12–16[Medline] [Order article via Infotrieve]
  30. Ikura, K., Kita, K., Fujita, I., Hashimoto, H., and Kawabata, N. (1998) Arch. Biochem. Biophys. 356, 280–286[CrossRef][Medline] [Order article via Infotrieve]
  31. Shevchenko, A., Wilm, M., Vorm, O., and Mann, M. (1996) Anal. Chem. 68, 850–858[Medline] [Order article via Infotrieve]
  32. McCormack, S. A., Wang, J.-Y., Viar, M. J., Tague, L., Davies, P. J. A., and Johnson, L. R. (1994) Am. J. Physiol. 267, C706–C714[Medline] [Order article via Infotrieve]
  33. Orrù, S., Ruoppolo, M., Francese, S., Vitagliano, L., Marino, G., and Esposito, C. (2002) Protein Sci. 11, 137–146[Abstract/Free Full Text]
  34. Farrace, M. G., Picarelli, A., Di Tola, M., Sabbatella, L., Marchione, O. P., Ippolito, G., and Piacentini, M. (2001) Cell Death Differ. 8, 767–770[CrossRef][Medline] [Order article via Infotrieve]
  35. Rivabene, R., Mancini, E., and De Vincenzi, M. (1999) Biochim. Biophys. Acta 1453, 152–160[Medline] [Order article via Infotrieve]
  36. Giovannini, C., Sanchez, M., Straface, E., Scazzocchio, B., Silano, M., and De Vincenzi, M. (2000) Toxicology 145, 63–71[CrossRef][Medline] [Order article via Infotrieve]
  37. Schreider, C., Peignon, G., Thenet, S., Chambaz, J., and Pincon-Raymond, M. (2002) J. Cell Sci. 115, 543–552[Abstract/Free Full Text]
  38. Hofer, D., Jons, T., Kraemer, J., and Drenckhahn, D. (1998) Ann. N. Y. Acad. Sci. 859, 75–84[Abstract/Free Full Text]
  39. Puszkin, E. G., and Raghuraman, V. (1985) J. Biol. Chem. 260, 16012–16023[Abstract/Free Full Text]
  40. Piredda, L., Amendola, A., Colizzi, V., Davies, P. J. A., Farrace, M. G., Fraziano, M., Gentile, V., Uray, I., Piacentini, M., and Fesus, L. (1997) Cell Death Differ. 4, 463–472[CrossRef][Medline] [Order article via Infotrieve]
  41. Chowdhury, Z. A., Barsigian, C., Chalupowicz, G. D., Bach, T. L., Garcia-Manero, G., and Martinez, J. (1997) Exp. Cell Res. 231, 38–49[CrossRef][Medline] [Order article via Infotrieve]
  42. Gautreau, A., Luovard, D., and Arpin, M. (2002) Curr. Opin. Cell Biol. 14, 104–109[CrossRef][Medline] [Order article via Infotrieve]
  43. Izawa, T., Fukata, Y., Kimura, T., Iwamatsu, A., Dohi, K., and Kaibuchi, K. (2000) Biochem. Biophys. Res. Commun. 278, 72–78[CrossRef][Medline] [Order article via Infotrieve]
  44. Walsh, S. V., Hopkins, A. M., Chen, J., Narumiya, S., Parkos, C. A., and Nusrat, A. (2001) Gastroenterology 121, 566–579[CrossRef][Medline] [Order article via Infotrieve]
  45. Singh, U. S., Kunar, M. T., Kao, Y. L., and Baker, K. M. (2001) EMBO J. 20, 2413–2423[CrossRef][Medline] [Order article via Infotrieve]
  46. Kubota, H., Hynes, G., Carne, A., Ashworth, A., and Willison, K., (1994) Curr. Biol. 4, 89–99[CrossRef][Medline] [Order article via Infotrieve]
  47. Ovelgonne, J. H., Koninkx, J. F., Pusztai, A., Bardocz, S., Kok, W., Ewen, S. W., Hendriks, H. G., and van Dikz, J. E. (2000) Gut 46, 679–687[Medline] [Order article via Infotrieve]
  48. Davies, P. J., Davies, D. R., Levitzki, A., Maxfield, F. R., Milhaud, P., Willinghan, M. C., and Pastan, I. H. (1980) Nature 283, 162–167[CrossRef][Medline] [Order article via Infotrieve]
  49. Pierce, K. L., Maudsley, S., Daaka, Y., Luttrell, L. M., and Lefkowitz, R. J. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 1489–1494[Abstract/Free Full Text]
  50. McPherson, P. S. (2002) Trends Cell Biol. 12, 312–315[CrossRef][Medline] [Order article via Infotrieve]
  51. Maki, M. (1995) Baillieres Clin. Gastroenterol. 9, 231–249[CrossRef][Medline] [Order article via Infotrieve]
  52. Clemente, M. G., Musu, M. P., Frau, F., Brusco, G., Sole, G., Corazza, G. R., and De Virgilis, S. (2000) Gut 47, 520–526[Abstract/Free Full Text]
  53. Collin, P., Kaukinen, K., Valimaki, M., and Salmi, J. (2002) Endocr. Rev. 23, 464–483[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Biol. Reprod.Home page
N. J Robinson, P. N Baker, C. J.P Jones, and J. D Aplin
A Role for Tissue Transglutaminase in Stabilization of Membrane-Cytoskeletal Particles Shed from the Human Placenta
Biol Reprod, October 1, 2007; 77(4): 648 - 657.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. ProteomicsHome page
S. Orru, A. Aspesi, M. Armiraglio, M. Caterino, F. Loreni, M. Ruoppolo, C. Santoro, and I. Dianzani
Analysis of the Ribosomal Protein S19 Interactome
Mol. Cell. Proteomics, March 1, 2007; 6(3): 382 - 393.
[Abstract] [Full Text] [PDF]


Home page
Protein Sci.Home page
Z. Keresztessy, E. Csosz, J. Harsfalvi, K. Csomos, J. Gray, R. N. Lightowlers, J. H. Lakey, Z. Balajthy, and L. Fesus
Phage display selection of efficient glutamine-donor substrate peptides for transglutaminase 2.
Protein Sci., November 1, 2006; 15(11): 2466 - 2480.
[Abstract] [Full Text] [PDF]